Patents by Inventor Kevin P. Cusack
Kevin P. Cusack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230066771Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.Type: ApplicationFiled: July 23, 2021Publication date: March 2, 2023Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
-
Publication number: 20210130293Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.Type: ApplicationFiled: October 16, 2019Publication date: May 6, 2021Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
-
Publication number: 20190055196Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.Type: ApplicationFiled: August 22, 2018Publication date: February 21, 2019Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
-
Patent number: 10106501Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.Type: GrantFiled: June 8, 2016Date of Patent: October 23, 2018Assignee: AbbVie Inc.Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
-
Publication number: 20160362370Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.Type: ApplicationFiled: June 8, 2016Publication date: December 15, 2016Applicant: AbbVie Inc.Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
-
Patent number: 9193744Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: GrantFiled: September 6, 2013Date of Patent: November 24, 2015Assignee: AbbVie Inc.Inventors: Andrew Burchat, Thomas D. Gordon, Kelly D. Mullen, David C. Ihle, Michael J. Morytko, Kevin P. Cusack, Gloria Y. Lo Schiavo, Lei Wang, Michael Friedman
-
Patent number: 9150592Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: GrantFiled: December 20, 2013Date of Patent: October 6, 2015Assignee: AbbVie Inc.Inventors: Kevin P. Cusack, Thomas D. Gordon, Michael Z. Hoemann, David C. Ihle, Bin Li, Gloria Y. Lo Schiavo, Gagandeep K. Somal, Michael Friedman, Martin E. Hayes, Wouter Iwema Bakker
-
Publication number: 20140179676Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: ABBVIE INC.Inventors: Kevin P. Cusack, Thomas D. Gordon, Michael Z. Hoemann, David C. Ihle, Bin Li, Gloria Y. Lo Schiavo, Gagandeep K. Somal, Michael Friedman, Martin E. Hayes, Wouter Iwema Bakker
-
Publication number: 20140162985Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: September 6, 2013Publication date: June 12, 2014Applicant: ABBVIE INC.Inventors: Andrew Burchat, Thomas D. Gordon, Kelly D. Mullen, David C. Ihle, Michael J. Morytko, Kevin P. Cusack, Gloria Y. Lo Schiavo, Lei Wang, Michael Friedman
-
Publication number: 20120238549Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: March 15, 2012Publication date: September 20, 2012Applicant: ABBOTT LABORATORIESInventors: Kevin P. Cusack, Thomas D. Gordon, David C. Ihle, Martin E. Hayes, Eric C. Breinlinger, Anna M. Ericsson, Bin Li, Lei Wang, Gloria Y. Martinez, Andrew Burchat, Adrian D. Hobson, Kelly D. Mullen, Michael Friedman, Michael J. Morytko
-
Patent number: 8217027Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.Type: GrantFiled: March 11, 2008Date of Patent: July 10, 2012Assignee: Abbott LaboratoriesInventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
-
Publication number: 20120053345Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.Type: ApplicationFiled: August 4, 2011Publication date: March 1, 2012Applicant: ABBOTT LABORATORIESInventors: Anna M. Ericson, Andrew Burchat, Kristine E. Frank, David J. Calderwood, Lily K. Abbott, Maria A. Argiriadi, David W. Borhani, Kevin P. Cusack, Richard W. Dixon, Thomas D. Gordon, Kelly D. Mullen, Robert V. Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude E. Barberis, Neil Wishart
-
Patent number: 8008481Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.Type: GrantFiled: April 2, 2007Date of Patent: August 30, 2011Inventors: Anna M. Ericsson, Andrew Burchat, Kristine E. Frank, David J. Calderwood, Lily K. Abbott, Maria A. Argiriadi, David W. Borhani, Kevin P. Cusack, Richard W. Dixon, Thomas D. Gordon, Kelly D. Mullen, Robert V. Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude E. Barberis, Neil Wishart
-
Publication number: 20110207704Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.Type: ApplicationFiled: August 24, 2010Publication date: August 25, 2011Applicant: ABBOTT LABORATORIESInventors: Kevin P. Cusack, Eric C. Breinlinger, Shannon R. Fix-Stenzel, Robert H. Stoffel, Kevin R. Woller, Adrian D. Hobson, Pintipa Grongsaard
-
Patent number: 7834039Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.Type: GrantFiled: December 14, 2007Date of Patent: November 16, 2010Assignee: Abbott LaboratoriesInventors: Adrian D. Hobson, Shannon R. Fix-Stenzel, Kevin P. Cusack, Eric C. Breinlinger, Graham K. Ansell, Robert H. Stoffel, Kevin R. Woller, Pintipa Grongsaard
-
Publication number: 20090069288Abstract: Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.Type: ApplicationFiled: July 15, 2008Publication date: March 12, 2009Inventors: Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Bin Li, Thomas D. Gordon, Robert H. Stoffel, Grier A. Wallace, Pintipa Grongsaard, Lu Wang, Lu Wang
-
Publication number: 20090029947Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.Type: ApplicationFiled: March 11, 2008Publication date: January 29, 2009Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
-
Publication number: 20080280876Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.Type: ApplicationFiled: December 14, 2007Publication date: November 13, 2008Inventors: Adrian D. Hobson, Shannon R. Fix-Stenzel, Kevin P. Cusack, Eric C. Breinlinger, Graham K. Ansell, Robert H. Stoffel
-
Patent number: 7091227Abstract: The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.Type: GrantFiled: February 6, 2001Date of Patent: August 15, 2006Assignee: Abbott GmbH & Co. KGInventors: Barbara Scott, Lee D. Arnold, Anna M. Ericsson, Kevin P. Cusack
-
Publication number: 20030153568Abstract: The present invention is directed to a compound of formula (I), 1Type: ApplicationFiled: February 6, 2001Publication date: August 14, 2003Applicant: BASF Aktiengesellschaft Ludwigshafen, GermanyInventors: Kevin P. Cusack, Barbara Scott, Lee D. Arnold, Anna M. Ericsson